The biotech industry stands at a crossroads, where unprecedented scientific potential collides with systemic inefficiencies that drive costs into the billions and slow life-saving innovation. As global competition intensifies, particularly from China, American biotech must confront not just technological gaps but deep-rooted structural and regulatory challenges that threaten its long-standing dominance.